5 November, 2019
Skadden is advising BeiGene, which today announced a global strategic oncology collaboration with Amgen for the commercialization and development in China of Amgen’s XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab), and the joint global development of 20 oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China. In connection with the collaboration, Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash at $174.85 per American Depositary Share (ADS). For more information, see BeiGene's press release.
Skadden served as legal advisor to BeiGene for Hong Kong Stock Exchange listing matters. The Skadden team includes corporate partner Christopher Betts, associate Allan Wan, and trainee solicitor Amy Liu.
Skadden is a leader in the biotechnology, healthcare and pharmaceutical sector. Our clients include one-half of the top 40 global pharmaceutical companies and one-quarter of the top 40 global medical device companies (by market capitalization), as well as numerous emerging biotechnology and health care businesses. We recently acted in connection with BeiGene, Innovent Biologics and CStone's initial public offerings on the Hong Kong Stock Exchange, Innovent Biologics' US$300m placing of new shares, as well as the proposed listings of two other high profile biotech sector companies recently filed with the Hong Kong Stock Exchange. In LMG Life Science’s 2019 rankings, Skadden is cited as a leading firm within the life sciences industry.
